AI Scientific Research Checklist for Healthcare & Biotech

Start with a specific use case such as histopathology triage, target identification in oncology, or adverse event signal detection rather than a broad goal like improving care. A sharply defined question helps align model design, endpoint selection, and eventual regulatory claims.

Connect the project to endpoints that matter in healthcare and biotech, such as sensitivity for rare disease detection, reduction in wet-lab screening cycles, or improved hit-to-lead conversion. This prevents teams from optimizing for proxy metrics that do not survive clinical or translational review.

Clarify whether the output is for clinicians, translational scientists, bioinformaticians, or assay development teams. The required latency, explainability, and interface design differ substantially between a tumor board support tool and a platform used by computational biologists.

Determine if the model informs diagnosis, treatment selection, patient risk scoring, or other functions that may place it under FDA, EMA, MHRA, or local device frameworks. Research-only tools have different evidence and documentation requirements than software influencing clinical care.

For biotech programs, outline how model outputs will move from hypothesis generation to validation in cell lines, organoids, animal studies, or clinical samples. For healthcare applications, specify whether the path includes retrospective validation, silent deployment, and prospective clinical evaluation.

Define thresholds for biological plausibility, assay confirmation rates, clinician acceptance, and data quality sufficiency before training. This reduces sunk-cost bias and keeps cross-functional teams aligned when early signals are mixed.

Confirm where genomic, imaging, EHR, pathology, and omics data originated, what consent language allows, and whether secondary AI use is permitted. Research data often carries site-specific restrictions that can block external model training or cross-border collaboration.

Check for imbalance by age, sex, ancestry, disease stage, scanner vendor, hospital system, and treatment history. In healthcare and biotech, hidden skews can produce misleading performance and weaken both clinical validity and payer confidence.

Use structures compatible with FHIR for clinical records, DICOM for imaging, and common bioinformatics conventions for sequencing and proteomics data. Standardization reduces integration friction and makes external validation and enterprise deployment far easier.

Remove direct identifiers, assess linkage risk, and test whether combinations of genomic and clinical variables could still expose individuals. This is especially important for rare disease datasets and biobank-linked cohorts where anonymity is harder to preserve.

Measure missingness, label consistency, batch effects, annotation agreement, assay drift, and imaging artifact rates before any model iteration. Weak labels and uncontrolled batch effects are common causes of irreproducible findings in biomedical AI.

Avoid leakage by splitting data across hospitals, trial sites, sequencing runs, or collection periods rather than by random row alone. Temporal and site-based separation better reflects real deployment conditions in healthcare environments.

If the system proposes protein sequences, edits, compounds, or wet-lab protocols, establish controls for restricted outputs, screening, and researcher access. Some biotech use cases require additional governance beyond standard privacy review.

Select approaches that fit the data and use case, such as transformers for longitudinal EHR, graph neural networks for molecular interaction networks, or foundation models for pathology imaging. Prioritize architectures that your team can validate, monitor, and support in production.

Compare performance to current standard practice, established statistical models, and simpler machine learning baselines. In regulated and clinical settings, a black-box model must beat credible alternatives, not just random chance or weak benchmarks.

Test whether the model is relying on hospital identifiers, slide preparation artifacts, treatment proxies, or sequencing batch signatures instead of biology. Shortcut learning is a recurring issue in medical imaging and biomarker discovery.

Provide calibrated confidence or abstention behavior for rare conditions, out-of-distribution samples, and low-quality inputs. Clinicians and lab teams need to know when the model is uncertain so they can escalate to manual review or additional assays.

Evaluate metrics separately for disease severity bands, treatment-naive versus pretreated patients, ancestry groups, pediatric versus adult populations, and assay platforms. Subgroup analysis is essential for both ethical deployment and reviewer scrutiny.

Use tools such as MLflow, Weights & Biases, DVC, or internal validated pipelines to preserve every training run and dataset snapshot. Reproducibility is especially important when findings may support publications, patents, or regulatory submissions.

Validate whether top features, embeddings, or generated hypotheses align with known pathways, biomarkers, tissue morphology, or pharmacology. Plausibility checks help separate meaningful discoveries from statistical artifacts.

Use realistic prevalence, noisy labels, incomplete records, and variable image quality rather than heavily curated subsets. Over-clean retrospective studies often overstate performance and fail during real deployment or peer review.

Run the model in parallel with current workflows to measure operational performance, calibration drift, and user response without influencing care decisions. Silent deployment is often the safest bridge between retrospective success and live clinical use.

Determine whether you need SaMD documentation, Good Machine Learning Practice alignment, analytical validation packages, or research-use-only labeling. Early pathway mapping reduces costly rework when commercialization discussions begin.

Maintain traceable records for requirements, risk analysis, training data, model changes, validation protocols, and post-market plans. Healthcare buyers and regulators often expect disciplined documentation similar to QMS-driven product development.

Set minimum values for sensitivity, specificity, positive predictive value, false alarm burden, and time saved based on the care setting or laboratory workflow. A model that is statistically impressive can still fail if it creates alert fatigue or poor triage utility.

Measure outcomes such as reduced read time, lower assay costs, fewer failed experiments, improved candidate prioritization, or shorter target validation cycles. Buyers in healthcare and biotech rarely invest on accuracy alone.

Plan interfaces for EHRs, LIS, PACS, LIMS, ELN, or internal discovery platforms rather than expecting users to adopt standalone tools. Adoption rises sharply when predictions appear inside the systems teams already use every day.

Specify when a clinician, pathologist, pharmacologist, or lab scientist must review, override, or confirm model outputs. Clear escalation rules are critical in settings where false positives and false negatives carry very different consequences.

Track changes in scanner hardware, sequencing chemistry, coding standards, patient mix, treatment guidelines, and disease prevalence over time. In healthcare and biotech, drift often comes from operational change rather than model failure alone.

Decide when retraining is allowed, what evidence is required, and whether updates need re-validation, customer notification, or regulatory review. Continuous learning sounds attractive, but uncontrolled changes can break trust and compliance.

Use role-based access, audit logs, secure enclaves, and vendor risk review for models touching PHI, proprietary compound libraries, or genomic IP. Commercial healthcare and biotech deals often depend as much on security posture as on model accuracy.

Create clear materials showing validation design, subgroup performance, workflow impact, implementation needs, and risk controls. Hospital systems, pharma partners, and biotech investors all want technical depth, but each group evaluates value differently.